- Home
- GRCE vs FGF Comparison
GRCE vs FGF Comparison
Compare GRCE & FGF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRCE
- FGF
- Stock Information
- Founded
- GRCE 2002
- FGF 2012
- Country
- GRCE United States
- FGF United States
- Employees
- GRCE N/A
- FGF N/A
- Industry
- GRCE
- FGF Property-Casualty Insurers
- Sector
- GRCE
- FGF Finance
- Exchange
- GRCE NYSE
- FGF Nasdaq
- Market Cap
- GRCE 30.9M
- FGF 28.0M
- IPO Year
- GRCE N/A
- FGF N/A
- Fundamental
- Price
- GRCE $3.53
- FGF $21.00
- Analyst Decision
- GRCE
- FGF
- Analyst Count
- GRCE 0
- FGF 0
- Target Price
- GRCE N/A
- FGF N/A
- AVG Volume (30 Days)
- GRCE 75.8K
- FGF 35.5K
- Earning Date
- GRCE 12-31-2024
- FGF 11-14-2024
- Dividend Yield
- GRCE N/A
- FGF N/A
- EPS Growth
- GRCE N/A
- FGF N/A
- EPS
- GRCE N/A
- FGF N/A
- Revenue
- GRCE N/A
- FGF $22,351,000.00
- Revenue This Year
- GRCE N/A
- FGF N/A
- Revenue Next Year
- GRCE N/A
- FGF N/A
- P/E Ratio
- GRCE N/A
- FGF N/A
- Revenue Growth
- GRCE N/A
- FGF N/A
- 52 Week Low
- GRCE $1.98
- FGF $14.21
- 52 Week High
- GRCE $4.97
- FGF $40.75
- Technical
- Relative Strength Index (RSI)
- GRCE N/A
- FGF 38.11
- Support Level
- GRCE N/A
- FGF $21.00
- Resistance Level
- GRCE N/A
- FGF $24.60
- Average True Range (ATR)
- GRCE 0.00
- FGF 3.08
- MACD
- GRCE 0.00
- FGF -0.93
- Stochastic Oscillator
- GRCE 0.00
- FGF 2.66
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
About FGF FG Financial Group Inc. (NV)
Fundamental Global Inc through its subsidiaries operates as diversified insurance, reinsurance, and investment management holding company. The company's segment includes Insurance and Asset Management. It generates maximum revenue from the Insurance segment.